Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
about
Stereotactic Radiosurgery for GlioblastomaTherapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future directionExternal beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastomaPhase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Anti-Epidermal Growth Factor Receptor Gene Therapy for GlioblastomaBevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme.Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.New Hypofractionation Radiation Strategies for Glioblastoma.Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma.A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.The radiosurgery fractionation quandary: single fraction or hypofractionation?Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas.Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.Focal or combined modality for the management of brain metastasis: did high tech radiotherapy superseded drug-radiotherapy combination?Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomasAberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival
P2860
Q26768680-771F739B-EC39-411D-947C-E79351A7FCF6Q26774717-E7187278-D78C-4634-A1ED-E6AAF7721F14Q28067135-37C75646-16F5-4C8E-A695-8A2A323071D6Q33419421-80BF6F43-AD0A-4EDA-94F9-F790BBA016EEQ33705268-7A75322E-90BE-4E5A-83B8-FD1963604241Q33786677-6BB6ABEA-F17F-49AC-B0BE-98EDEF1E0052Q34293163-B3A2D0D8-47C8-4332-BC14-19DF5FD56E81Q36155208-A7E76EF3-10DD-4D74-9CA7-62A87E7C0F4AQ36391485-01F1CFE7-F4BF-4DA8-B61A-1F02393CD699Q36705917-2C8FF9C5-F9FA-485A-B32E-F3EBBD39DD97Q38666254-3530FCCF-6C3A-4C2B-8D3E-68D44872BBCCQ38674157-D7618353-0379-4820-AF3C-721B0CD3AA80Q38815396-D959A3F6-8DA7-4640-AEF7-17A12E948AB6Q39339970-BC727B22-BD19-4082-A0DF-A3DE3E4678B8Q39366992-3E1C1896-BE16-4997-A2AE-58F746DA576CQ39616746-0E3435A2-C2FD-4C5B-98D4-1F1A3FCDA2D2Q40095195-DC9AE016-E427-458C-B7CF-F2CAE4737923Q41706326-3E7000D8-DADB-4C63-971A-91F9D1500649Q44455124-8BAF9EFD-E719-4EF3-84A6-234CFD3462A9Q46004791-5E983484-84D7-4061-8C32-2068A68A6C2DQ47128299-256C87F5-16A1-47F2-95DC-098ED3E3B3F8Q48204927-85773D5B-B548-4AE3-ACAA-4AFD25489EA7Q48485046-6304C22F-5782-40AC-AEFB-7D19E120A265Q49499240-E7E3D6A0-210D-48F6-9EF0-B0CEF14CE408Q53701730-AACD405E-6113-458D-A8CE-344FF4E6B7BCQ54153689-38F0F78F-B496-468B-99EA-1B7963BBF7EDQ55278851-01E5D964-7DA5-4A38-916F-3B10A500D684Q57177114-FCE414E7-B034-4C44-B0FE-A6350DA55829Q57296293-06EB6412-6A01-4319-8FB1-E2D194D6C05E
P2860
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Phase II study of bevacizumab, ...... newly diagnosed glioblastoma.
@ast
Phase II study of bevacizumab, ...... newly diagnosed glioblastoma.
@en
type
label
Phase II study of bevacizumab, ...... newly diagnosed glioblastoma.
@ast
Phase II study of bevacizumab, ...... newly diagnosed glioblastoma.
@en
prefLabel
Phase II study of bevacizumab, ...... newly diagnosed glioblastoma.
@ast
Phase II study of bevacizumab, ...... newly diagnosed glioblastoma.
@en
P2093
P2860
P50
P1476
Phase II study of bevacizumab, ...... r newly diagnosed glioblastoma
@en
P2093
Adilia Hormigo
Andrew B Lassman
Denise D Correa
Elena Pentsova
Geraldine Faivre
Ingo Mellinghoff
Jason T Huse
Jianan Zhang
Juan Sanchez
Katherine S Panageas
P2860
P304
P356
10.1158/1078-0432.CCR-14-0822
P407
P50
P577
2014-08-08T00:00:00Z